Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Tailoring Management for Invasive Lobular Carcinoma: Imaging, Surgical Treatment, and Systemic Therapy Considerations.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: April 07, 2026
Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.
Journal: ESMO open
Published: November 04, 2025
Ultra-high tumor mutation burden breast cancer: genomic profiling and real-world immunotherapy results.
Journal: NPJ breast cancer
Published: August 27, 2025
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study.
Journal: Breast cancer research : BCR
Published: January 30, 2025
The state of the science of oral selective oestrogen receptor degraders.
Journal: The Lancet. Oncology
Published: July 31, 2024
Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) advanced breast cancer.
Journal: ESMO open
Published: June 25, 2024
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Journal: Cancer research communications
Published: October 26, 2022
Objective Impact of Hematology-Oncology Hospitalist Care in an Inpatient Setting.
Journal: JCO oncology practice
Published: August 19, 2022
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial.
Journal: NPJ breast cancer
Published: April 25, 2022
Lower Socioeconomic Status is Associated With Decreased Therapeutic Response to the Biologic Agents in Psoriasis Patients.
Journal: Journal of drugs in dermatology : JDD
Published: February 18, 2016
Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Journal: Journal of drugs in dermatology : JDD
Published: August 13, 2015
Showing 1-12 of 12
Last Updated: 09/26/2026